Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Summary

Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood) will also be measured.

Timeline

Start

2023-11-25

Primary completion

2024-05-03

Completion

2024-07-18

Drugs

Indications